Drugs / JINZHEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05092503 | May 2022 → May 2023 | COVID-19 | Lianyungang Kanion Group, Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JINZHEN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05092503 ↗ |
| Known as | JINZHEN Granules for Oral Solution | “This study is to evaluate the safety and efficacy of JINZHEN Granules for Oral Solution compared to placebo for treatment of mild to moderate COVID-19 outpatients.” NCT05092503 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “JINZHEN is a botanical drug” NCT05092503 ↗ |
| Route | Oral | “JINZHEN granules will be dissolved in drinking water and administered orally.” NCT05092503 ↗ |